Budez CR (Budesonide) 3 mg Controlled-Release Capsules

Budez CR delivers budesonide as a 3 mg oral controlled-release capsule, and we offer it in packs of 30, 60, 90, and 180 capsules so customers can match a package to the length of course their prescriber has set out. This guide walks through what the capsule contains, how it is generally used, what to watch for during treatment, and how to store or dispose of it once a course is finished.

Medicine overview: Budez CR

Composition and active ingredients

Each Budez CR capsule contains 3 mg of budesonide, a synthetic corticosteroid formulated for controlled release in the bowel. Its coated granules are designed to deliver budesonide to the ileum and ascending colon, the segments of the bowel commonly affected in Crohn's disease. Because the drug acts largely at the site of inflammation and undergoes extensive first-pass metabolism in the liver, it produces meaningfully less whole-body corticosteroid exposure than older oral steroids such as prednisone, while still reducing local inflammation effectively.

Use cases

Budesonide capsules in this controlled-release form are established for treating mild-to-moderate active Crohn's disease involving the ileum and/or ascending colon in adults. A treatment course commonly runs around eight weeks, and some prescribers use a lower maintenance dose afterward or a tapering schedule rather than stopping abruptly. Budez CR is not interchangeable with inhaled budesonide used for asthma or with budesonide nasal sprays; the identity, release pattern, and intended use of this oral capsule are specific to bowel disease, and we keep our listing limited to that exact product.

Prescription requirement

Budesonide is classified as a prescription medicine in Canada, and a diagnosis of Crohn's disease together with an appropriate course length is normally confirmed by a physician or gastroenterologist before treatment begins. We do not require a prescription document to accept an order for Budez CR, which lets customers place an order without that extra step; this reflects our own checkout process rather than a change in budesonide's prescription status in Canada, and we still encourage discussing this treatment with a doctor or pharmacist before starting or adjusting it. We should also note that Budez CR does not currently appear as an authorized product in Health Canada's Drug Product Database, and no confirmed Canadian sponsor or Drug Identification Number has been identified for this exact capsule, even though the same active ingredient is authorized under other brand names elsewhere.

General dosing and warnings for Budez CR

How and when to take Budez CR

A typical adult regimen for active disease uses 9 mg of budesonide once daily, taken as three of the 3 mg Budez CR capsules together in the morning, generally continued for around eight weeks as directed by a prescriber. The capsules should be swallowed whole with a glass of water and should not be crushed or chewed, since damaging the controlled-release granules can change where the medicine is released. Do not open a capsule unless the product leaflet or a pharmacist specifically confirms an appropriate method for this exact formulation. Budez CR can generally be taken with or without food, though taking it consistently in the same way and at the same time each morning helps maintain a regular dosing routine. Any change in dose, including a taper toward the end of a course, should follow a prescriber's specific instructions rather than a general schedule.

Missed dose

If a dose of Budez CR is missed, it should be taken as soon as it is remembered on the same day. If it is already close to the time of the next scheduled dose, the missed dose should be skipped rather than doubled, and the regular schedule resumed the next day. Taking two doses together to make up for a missed one is not advised, since it increases short-term corticosteroid exposure without added therapeutic benefit.

Overdose

A single extra dose of Budez CR is unlikely to cause dramatic symptoms, but taking substantially more than directed, or continuing high doses for longer than intended, can push corticosteroid effects higher than the treatment is meant to produce, including fluid retention, elevated blood sugar, mood changes, or signs of excess cortisol activity. Anyone who has taken considerably more than prescribed, or who develops unusual symptoms after doing so, should contact a poison control centre or seek medical attention promptly, and should bring the Budez CR packaging along so the exact strength and quantity involved can be confirmed.

Precautions before and during treatment

Allergy warnings

Budez CR should not be used by anyone with a known hypersensitivity to budesonide or to any of the capsule's other ingredients. Signs of an allergic reaction, such as rash, itching, swelling of the face or throat, or difficulty breathing, warrant stopping the medicine and seeking prompt medical care. An allergy history unrelated to budesonide or its excipients is not by itself a reason to avoid this capsule, but it is worth mentioning to a prescriber before starting.

Health condition warnings

Because budesonide is a corticosteroid, several health conditions call for extra caution or monitoring. People with active or latent tuberculosis, untreated infections, or a history of glaucoma or cataracts should discuss these with a prescriber first, since corticosteroids can affect eye pressure and can mask or worsen infection. Liver impairment matters specifically for this capsule, since budesonide is metabolized mainly through the liver and reduced liver function can raise the amount of drug reaching general circulation. People with diabetes may see changes in blood glucose control and should monitor levels more closely during treatment. Long or repeated courses can affect bone density and the body's own adrenal hormone production, so prescribers may check bone health or adrenal function with extended use. Pregnancy and breastfeeding both call for an individual discussion with a prescriber, since budesonide passes into breast milk in small amounts and pregnancy data are limited. Use of controlled ileal-release budesonide for Crohn's disease is established only from around 8 years of age and roughly 25 kg body weight, with age- or weight-specific dosing, limited treatment duration, and monitoring of growth and adrenal function; use in younger or smaller children is not established.

Side effects of Budez CR

Most people tolerate short courses of Budez CR reasonably well, though some corticosteroid-related effects are common. These typically include headache, nausea or indigestion, mild abdominal discomfort, back pain, dizziness, and symptoms resembling a respiratory infection. Less commonly, longer or repeated courses can bring more typical steroid effects such as acne, rounding of the face, increased appetite, sleep disturbance, or mood changes.

A smaller number of effects deserve prompt attention rather than simply waiting them out. These include signs of adrenal insufficiency after stopping treatment, such as fatigue, nausea, or dizziness on standing, which can occur if the body's own cortisol production has been suppressed during a longer course. Vision changes, severe or worsening abdominal pain, signs of a new or worsening infection such as fever or persistent sore throat, and any sign of a serious allergic reaction should all prompt contact with a doctor or, in urgent cases, emergency care.

Medicine interactions with Budez CR

Budesonide is broken down mainly through the CYP3A4 liver enzyme pathway, so medicines that strongly inhibit this enzyme can raise budesonide levels considerably. These include certain antifungal medicines such as ketoconazole and itraconazole, some antibiotics such as clarithromycin, HIV protease inhibitors such as ritonavir, and grapefruit or grapefruit juice; combining these with Budez CR is generally avoided or requires close medical supervision. Conversely, medicines that induce this enzyme, such as rifampicin or certain anti-seizure drugs, can reduce budesonide's effect. Other corticosteroids taken by mouth, injection, or inhalation add to overall steroid exposure and are usually avoided in combination with Budez CR unless a prescriber has specifically planned it that way. Cholestyramine may reduce budesonide absorption if taken close to the same time, so a pharmacist or prescriber may recommend spacing the doses apart. Regular use of NSAIDs alongside a corticosteroid can raise the risk of stomach irritation or ulcers. Live vaccines may be unsuitable when corticosteroid exposure is sufficient to suppress immune function, so vaccination plans should be reviewed with a prescriber rather than assuming every vaccine must be avoided. A full personal medication list, including over-the-counter products and supplements, is worth reviewing with a pharmacist before starting Budez CR.

After using Budez CR

Storage

Store Budez CR capsules below 25°C, protected from direct light and moisture. Avoid humid locations such as a bathroom cabinet. Keeping the capsules in their original, tightly closed container helps protect the medicine and keeps it out of reach of children and pets. Capsules that look damaged, discoloured, or past their printed expiry date should not be taken.

Disposal

Leftover or expired Budez CR should not be thrown into household trash or flushed down the toilet. Most Canadian pharmacies accept unused prescription medicines through a medication take-back program at no charge, and this remains the simplest and safest way to dispose of any capsules that are no longer needed.

Budez CR capsules compared with other oral options

Several other options exist for people who need a comparable or different approach to Crohn's disease, though their formulations and roles should not be treated as interchangeable. Other controlled ileal-release budesonide capsules, such as Entocort EC or Budenofalk, contain the same active ingredient and are the closest formulation-based comparisons, but their availability, labelling, and release characteristics may differ. Colonic-release budesonide tablets such as Cortiment or Uceris are designed mainly for ulcerative colitis and are not direct substitutes for an ileal-release Crohn's disease capsule. Mesalamine products belong to a different drug class and are used mainly for ulcerative colitis; evidence does not support treating them as a routinely effective replacement for budesonide in active Crohn's disease. When a broader-acting oral corticosteroid is appropriate, conventional tablets such as Prednisolone may be considered for induction treatment, though their systemic action generally produces a different and potentially greater burden of corticosteroid side effects. Anyone comparing these choices should discuss disease severity, location, previous treatment response, and maintenance plans with a prescriber rather than switching therapies independently. For a broader look at related digestive-health treatments we carry, visit our Gastrointestinal Tract section.